TapewireFind a company

person · Reporting owner

Ege David S.

Disclosed activity across 1 company

Tapewire entity
88219
SEC CIK
0001829360

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Seres Therapeutics, Inc.MCRB · Entity 7191See RemarksAugust 15, 2024August 19, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Seres Therapeutics, Inc.

Report date August 15, 2024 · Filed August 19, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect77,575 Ending reported balance After 2024-08-16 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2024-08-15 · Exercise / conversion · Acquired 2,969 · Balance 78,703

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Row 2 · 2024-08-16 · Sale · Disposed 1,128 · Balance 77,575

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $ 0.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect29,688 Reported balance After 2024-08-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-08-15 · Exercise / conversion · Disposed 2,969 · Balance 29,688

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $ 0.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 16, 2024 Filed Aug 19, 2024 21:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 1,128 $0.84 $947.52
Disclosure

SEC source: 0000950170-24-098699 · ownership.xml · nonDerivative · entry 2

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,575

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $ 0.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 2,969 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-098699 · ownership.xml · derivative · entry 3

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,688

Underlying: Common Stock · 2,969 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 21:29 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 2,969 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-098699 · ownership.xml · nonDerivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
May 15, 2024 Filed May 18, 2024 00:16 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 2,968 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-062056 · ownership.xml · derivative · entry 3

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,657

Underlying: Common Stock · 2,968 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
May 15, 2024 Filed May 18, 2024 00:16 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 1,090 $0.94 $1,024.60
Disclosure

SEC source: 0000950170-24-062056 · ownership.xml · nonDerivative · entry 2

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,734

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 15, 2024 Filed May 18, 2024 00:16 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 2,968 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-062056 · ownership.xml · nonDerivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
February 16, 2024 Filed Feb 17, 2024 02:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 5,010 $1.08 $5,410.80
Disclosure

SEC source: 0000950170-24-016688 · ownership.xml · nonDerivative · entry 2

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,856

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 15, 2024 Filed Feb 17, 2024 02:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 11,875 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-016688 · ownership.xml · derivative · entry 6

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,625

Underlying: Common Stock · 11,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F7 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F7 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
February 15, 2024 Filed Feb 17, 2024 02:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 11,875 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-016688 · ownership.xml · nonDerivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,866

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Read SEC document
February 14, 2024 Filed Feb 17, 2024 02:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantRestricted Stock Units · Derivative 31,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-016688 · ownership.xml · derivative · entry 5

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F6 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F6 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Read SEC document
February 14, 2024 Filed Feb 17, 2024 02:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantStock Option (Right to Buy) · Derivative 287,905 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0000950170-24-016688 · ownership.xml · derivative · entry 4

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 287,905

Underlying: Common Stock · 287,905 shares

Expires 2034-02-13

F5 · derivative.exercise_date: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.

Read SEC document
February 14, 2024 Filed Feb 17, 2024 02:15 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantStock Option (Right to Buy) · Derivative 187,500 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0000950170-24-016688 · ownership.xml · derivative · entry 3

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2034-02-13

F4 · derivative.exercise_date: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 01:39 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon Stock 4,066 $1.35 $5,489.10
Disclosure

SEC source: 0000899243-23-020075 · doc4.xml · nonDerivative · entry 2

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,991

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.

F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3425 to $1.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 27, 2023 Filed Nov 1, 2023 01:39 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionRestricted Stock Units · Derivative 11,361 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-020075 · doc4.xml · derivative · entry 4

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,360

Underlying: Common Stock · 11,361 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.

F1 · shares: On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.

F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.

F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.

Read SEC document
October 27, 2023 Filed Nov 1, 2023 01:39 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 Exercise / conversionCommon Stock 11,361 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-020075 · doc4.xml · nonDerivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.

Read SEC document
April 28, 2023 Filed May 1, 2023 20:46 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon stock 7,038 $5.19 $36,527.22
Disclosure

SEC source: 0000899243-23-011945 · doc4.xml · nonDerivative · entry 2

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,696

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 3, 2021, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.0350 to $5.1900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 27, 2023 Filed May 1, 2023 20:46 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantCommon stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-011945 · doc4.xml · nonDerivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,734

F1 · kind: On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 20,000 shares.

Read SEC document
April 27, 2023 Filed Nov 1, 2023 01:39 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantRestricted Stock Units · Derivative 22,721 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-020075 · doc4.xml · derivative · entry 3

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,721

Underlying: Common Stock · 22,721 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.

F1 · shares: On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.

F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.

F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.

Read SEC document
February 03, 2023 Filed Feb 7, 2023 22:50 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantStock Option (Right to Buy) · Derivative 95,000 $0.00 Strike: $5.50 $0.00
Disclosure

SEC source: 0000899243-23-004211 · doc4.xml · derivative · entry 2

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2033-02-02

F3 · derivative.exercise_date: The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Read SEC document
February 03, 2023 Filed Feb 7, 2023 22:50 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantRestricted Stock Units · Derivative 47,500 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-004211 · doc4.xml · derivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,500

Underlying: Common Stock · 47,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.

F2 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.

Read SEC document
October 31, 2022 Filed Oct 31, 2022 23:37 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 SaleCommon stock 5,012 $7.93 $39,745.16
Disclosure

SEC source: 0000899243-22-034598 · doc4.xml · nonDerivative · entry 2

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,734

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Read SEC document
October 27, 2022 Filed Oct 31, 2022 23:37 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantCommon stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-034598 · doc4.xml · nonDerivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,746

F1 · kind: On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 20,000 shares.

Read SEC document
July 05, 2022 Filed Jul 6, 2022 23:22 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantCOMMON STOCK 31,746 $3.15 $99,999.90
Disclosure

SEC source: 0000899243-22-025514 · doc4.xml · nonDerivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,746

Read SEC document
February 04, 2022 Filed Feb 9, 2022 02:30 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantStock Option (Right to Buy) · Derivative 175,000 $0.00 Strike: $7.38 $0.00
Disclosure

SEC source: 0000899243-22-005320 · doc4.xml · derivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2032-02-03

F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Read SEC document
October 19, 2020 Filed Oct 21, 2020 21:02 UTC Seres Therapeutics, Inc. MCRB · Entity 7191 GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $32.60 $0.00
Disclosure

SEC source: 0000899243-20-028909 · doc4.xml · derivative · entry 1

Ege David S. · CIK 0001829360 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2030-10-18

F1 · derivative.exercise_date: The option will vest as to 25% of the shares on October 19, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.